Reed Smith advises Logiprem-F on sale to Evolucare Technologies

Reed Smith advised the shareholders of Logiprem-F, and GWL Avocats advised the purchaser, Evolucare Technologies. The transaction concerned the transfer of 100% of the capital and voting rights of Logiprem-F to Evolucare Technologies, the French subsidiary of Italian group GPI, a specialist in healthcare software solutions. Simultaneously, 11% of the company was transferred to Logiprem-F’s principal managers, resulting in Evolucare Technologies holding 89% of the share capital. Logiprem-F develops Logipren, a SaaS platform that supports medication prescribing for neonatology and pediatric intensive care units. The company is the market leader in France for this niche, supporting more than 90 hospitals and employing around 40 staff, and secures the full prescribing and administration pathway for newborns and young patients. The acquisition forms part of Evolucare and the GPI group’s strategy to strengthen their critical care division and to consolidate their position as a leading European provider of critical care software, particularly in France and other major European markets. Reed Smith represented the shareholders of Logiprem-F with a team composed by: Marc Fredj (Partner), Antéa Bonito (Associate), and Camille Diz (Legal Counsel). GWL Avocats represented Evolucare Technologies with a team composed by: Siham Belarbi (Partner).

Reed Smith advises Logiprem-F on sale to Evolucare Technologies

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads